NCT07019259 Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors
| NCT ID | NCT07019259 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-06-30 |
| Primary Completion | 2027-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2025-06-30 with a primary completion date of 2027-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.
Eligibility Criteria
Inclusion Criteria: * History of childhood cancer (\<21 years of age at diagnosis) * Current age five years or older (due to availability of validated measures for CIPN in this age group) * History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN * CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors \<18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation) Exclusion Criteria: * Currently Pregnant or lactating (by patient report, at initiation or at any point of the study) * Inability to sit still for at least 15 minutes * Diagnosis of neuropathy prior to cancer treatment * Active cancer diagnosis or cancerous skin lesion * Central nervous system tumor (due to lack of validated measures for CIPN in this population) * Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.
Contact & Investigator
Rozalyn Rodwin, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07019259 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07019259 currently recruiting?
Yes, NCT07019259 is actively recruiting participants. Contact the research team at rozalyn.rodwin@yale.edu for enrollment information.
Where is the NCT07019259 trial being conducted?
This trial is being conducted at New Haven, United States, Trumbull, United States.
Who is sponsoring the NCT07019259 clinical trial?
NCT07019259 is sponsored by Yale University. The principal investigator is Rozalyn Rodwin, MD at Yale University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.